Opportunities and challenges following approval of resmetirom for MASH liver disease
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Few MASH patients show fibrosis regression, and the exact drivers of fibrosis progression remain unclear.
“Although several drugs are currently in the pipeline, with resmetirom recently approved for MASH3, most patients do not have evidence of fibrosis improvement and the precise mechanisms driving its progression are incompletely understood.”
Apart from resmetirom, recently approved by the FDA for use in patients with MASH with moderate to advanced liver fibrosis, there are no other therapeutic options for this disease.
“Apart from resmetirom, recently approved by the FDA for use in patients with MASH with moderate to advanced liver fibrosis, there are no other therapeutic options for this disease92.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 14 · Cited by 60
Research works printed but not linked: 7
- Rinella, M.E., et al. Annals of Hepatology, 101133 (2023).
- Younossi, Z.M., et al. Hepatology 77, 1335 (2023).
- Elizabeth, L.Y. & Schwimmer, J.B. Clinical Liver Disease 17, 196 (2021).
- Asquith, E., Bould, K., Catling, J., Day, E. & Holt, A. BMC gastroenterology 23, 306 (2023).
- Cannon, C.E. International Journal of Environmental Research and Public Health 17, 2303 (2020).
- Lazarus, J.V., et al. Journal of Hepatology 79, 618-634 (2023).
- Ratziu, V. & Charlton, M. Journal of Hepatology (2023).
- Authors
- Lazarus, J. V., Ivancovsky Wajcman, D., Mark, H. E., Younossi, Z. M., Kopka, C. J., Cohen, N., Bansal, M. B., Betel, M., & Brennan, P. N.
- Affiliations
- City University of New York (US)
- Barcelona Institute for Global Health (ES)
- Inova Health System (US)
- Icahn School of Medicine at Mount Sinai (US)
- Fatty Liver Alliance (CA)
- University of Dundee (GB)
- Corresponding author
- Lazarus, Jeffrey V.
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-04-19
- Volume
- 30
- Issue
- 12
- Pages
- 3402-3405
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4394962630
- Cited by
- 60
- References
- 14
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 15
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Centres de Recerca de Catalunya (CEX2018-000806-S, 501100011033, MCIN/AEI/10.13039/501100011033)
- Generalitat de Catalunya (10.13039/501100011033, 501100011033, CEX2018-000806-S, MCIN /AEI/10.13039/501100011033)
- Agencia Estatal de Investigación (AEI//10.13039/501100011033/, 501100011033, 10.13039/501100011033, MCIN/AEI/10.13039/501 100 011 033, 13039, .13039/501100011033, 10.13039, AEI/10, CEX2018-000806-S)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Keywords
- resmetirom, nonalcoholic steatohepatitis, MASH, drug approval, FDA approval, access to medicines, health care system
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
